| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT07528352 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for… |
Recruitment opened |
| 2026-06-05 | NCT07528352 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for… |
date change Primary completion pushed: 2030-05 -> 2030-06 |
| 2026-06-05 | NCT07528352 External Beam Radiotherapy Followed by Bispecific Antibody Therapy for… |
date change Completion pushed: 2031-05 -> 2031-06 |
| 2026-06-04 | NCT06994169 Glofitamab in Real Life |
date change Completion pushed: 2026-07-30 -> 2026-12-30 |
| 2026-05-30 | NCT04077723 A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of… |
Trial sites reduced: 44 -> 35 locations |
| 2026-05-27 | NCT04889716 CAR-T Followed by Bispecific Antibodies |
Primary endpoint(s) modified |
| 2026-05-27 | NCT04889716 CAR-T Followed by Bispecific Antibodies |
Enrollment reduced: 42 -> 23 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-08 | NCT07634289 Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell… | Phase 2 | Not Yet Recruiting |
| 2026-05-29 | NCT07613788 Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL | Phase 2 | Not Yet Recruiting |
| 2026-05-20 | NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… | Phase 2 | Not Yet Recruiting |
| 2026-05-19 | NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06084936 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in… | Lymphoma | Recruiting |
| NCT06047080 | An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab… | Large B-Cell Lymphoma | Active, Not Recruiting |
| NCT04408638 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs… | Diffuse Large B-cell Lymphoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06054776 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory… | Mantle Cell Lymphoma | Recruiting |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06213311 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or… | B Cell Lymphoma | Recruiting |
| NCT06558604 | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell… | Lymphoma, Mantle-Cell | Recruiting |
| NCT05800366 | A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse… | Lymphoma | Recruiting |
| NCT07460362 | Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory… | MCL | Recruiting |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Mantle Cell Lymphoma | Recruiting |
| NCT06050694 | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG… | Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting |
| NCT07257055 | Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High… | Phase 2 Study | Recruiting |
| NCT04889716 | CAR-T Followed by Bispecific Antibodies | Large B-cell Lymphoma | Recruiting |
| NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for… | B-Cell Non-Hodgkins Lymphoma | Recruiting |
| NCT07003295 | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type… | Recurrent Mantle Cell Lymphoma | Recruiting |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | Diffuse Large B Cell Lymphoma (DLBCL) | Recruiting |
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | DLBCL - Diffuse Large B Cell Lymphoma | Not Yet Recruiting |
| NCT07387848 | Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in… | Diffuse Large B Cell Lymphoma Refractory | Not Yet Recruiting |
| NCT04980222 | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab… | Lymphoma | Active, Not Recruiting |
| NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | Follicular Lymphoma | Active, Not Recruiting |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory… | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Active, Not Recruiting |
| NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse… | Diffuse Large B Cell Lymphoma | Not Yet Recruiting |
| NCT05798156 | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With… | Lymphoma, Large B-Cell, Diffuse | Active, Not Recruiting |
| NCT07453095 | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following… | Mantle Cell Lymphoma | Not Yet Recruiting |
| NCT07594899 | AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | Large B-Cell Lymphoma (LBCL) | Not Yet Recruiting |